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A new perspective on the application of mosquito repellents
Great eﬀ ort is expended in understanding the eﬀ ect 
of malaria control interventions on the plasmodium 
parasite and its anopheles mosquito vector. However, 
no intervention will work unless it is properly 
used, and human behaviour is not always carefully 
considered during controlled trials of vector control 
interventions. A study in The Lancet Infectious Diseases 
by Vincent Sluydts and colleagues1 showed that 
community-scale distribution of free topical mosquito 
repellents in Cambodia did not reduce malaria 
transmission because of human behaviour. In the 
study area, a high proportion of malaria vectors bite 
outdoors in the evenings when people are active;2 
therefore, theoretically a mosquito repellent could 
prevent malaria in this setting. However, even though 
the repellent was freely available and highly eﬀ ective,3 
the authors also did a mixed-methods study and 
discovered that only 8% of participants regularly used 
it,4 despite 70% reporting daily use. User compliance 
is diﬃ  cult to measure in trials and the study team 
used parallel observational studies4 to show disparity 
between reported and actual compliance with the 
intervention. Low compliance resulted in a non-
signiﬁ cant association between repellent allocation 
and malaria risk. This study is the largest and most 
comprehensive controlled study done to measure the 
eﬀ ect of mosquito repellents for additional malaria 
control when used in conjunction with long-lasting 
insecticidal nets.
This cluster randomised trial1 included roughly 
25 000 participants in each study group (picaradin 
mosquito repellent vs identical placebo), and regularly 
screened around 2500 participants per group for 
malaria with sensitive molecular diagnostics. This 
robust design gives strong evidence that distribution 
of eﬀ ective personal protection tools do not 
necessarily translate into protective eﬃ  cacy against 
clinical malaria at an individual or community level. 
If compliance with repellents is suboptimum and 
requires substantial behavioural change by users, 
repellents are unlikely to be selected by donors for 
inclusion in programmatic malaria control.
Topical insect repellents are excellent tools for 
personal mosquito bite prevention with a long history 
of use and excellent safety proﬁ les.5 Although several 
controlled trials have shown that repellents do prevent 
malaria, a systematic review and meta-analysis 
showed no overall trend in protective eﬃ  cacy.6 Topical 
repellents are an imperfect vector control tool simply 
because they must be used frequently, inevitably 
resulting in inconsistent compliance and incorrect 
application.7 Even soldiers who are well educated 
about repellents did not apply them daily if they did 
not perceive a biting nuisance or risk of disease.8
Massive scaling up of malaria vector control has 
averted an estimated 663 million clinical cases 
of malaria in Africa through widespread free or 
subsidised distribution of long-lasting insecticidal nets 
that kill mosquitoes attempting to feed on people 
sleeping under them and spraying of dwellings with 
residual insecticides that kill mosquitoes resting inside 
houses (68% and 11% of cases averted, respectively).9 
However, in many malaria endemic regions including 
South America10 and southeast Asia,11 malaria vectors 
have a high preference for outdoor and early evening 
feeding which means that they do not often come into 
contact with either long-lasting insecticidal nets or 
residual insecticides used indoors. Worryingly, in some 
areas of Africa, the proportion of control achievable 
through residual insecticides and long-lasting 
insecticidal nets might decline as vectors evolve 
resistance to insecticides12 or adapt to bite during the 
evenings or mornings when people are not under 
their long-lasting insecticidal nets because this is the 
only time they can ﬁ nd their preferred blood host 
unprotected.13
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Therefore, a method to prevent malaria transmission 
outside of sleeping hours is urgently needed 
for malaria elimination: ideally one that will kill 
mosquitoes. However, there remains an absence of 
existing tools with this capacity. Fortunately, several 
tools are in development with good potential for 
future implementation, including toxic sugar baits14 
and killing stations baited with synthetic human 
odours.15 There is also renewed interest in the use 
of larval source management to kill immature 
mosquitoes. 
Although the large-scale distribution of topical 
repellents might not ﬁ ll the requirement for community 
malaria protection outside of sleeping hours, repellents 
are still useful. Providing repellents to speciﬁ c risk groups 
that potentially contribute disproportionately to malaria 
trans mission16 and development of longer-lasting personal 
protection measures needing minimum com pliance (eg, 
insecticidal clothing that protects for 3–6 months17) should 
be pursued. Additionally, travellers to malaria endemic 
areas are strongly advised to use repellents because they 
are highly eﬀ ective bite prevention tools when used 
correctly and consistently.
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Reducing unnecessary antibiotic exposure in preterm 
neonates: an achievable goal
In The Lancet Infectious Diseases, Joseph Cantey and 
colleagues1 describe how in their neonatal intensive 
care unit, a stewardship strategy aimed at decreasing 
antibiotic exposure was safely and eﬀ ectively imple-
mented through two simple steps. First, continuation 
of empirical antibiotic therapy beyond 48 h for 
ruled-out sepsis courses was stopped by setting the 
electronic medical record to discontinue it after 
48 h. Second, duration of therapy for pneumonia 
and culture-negative sepsis was limited to 5 days. 
In doing so, a 27% reduction in antibiotic use (from 
343·2 days of therapy per 1000 patient-days at 
baseline to 252·2 days of therapy per 1000 patient-
days after the intervention) was obtained.
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